1. Pre-clinical trials ready Biosimilar monoclonal antibodies (mAb) technologies for several patent expired/soon to be expired drugs.
2. Rapid development of Chimeric Antigen Receptor (CAR) T-cell technology for Multiple myeloma, Pancreatic and Ovarian cancers